Company Overview
Enanta Pharmaceuticals, Inc. operates as a biotechnology firm focused on the discovery and development of small molecule drugs targeting virology and immunology indications. The company functions within the broader healthcare sector, specifically the biotechnology industry, where it utilizes scientific research to advance therapeutic options for specific medical conditions. In terms of scale, the company reports a market capitalization of $353.17M, generates annual revenue of $66.98M, and employs a workforce of 120 individuals. These financial figures indicate that Enanta holds a mid-cap position in the market, suggesting it has moved beyond the initial startup phase but has not yet achieved the massive revenue streams typical of established pharmaceutical giants with diversified product portfolios.
Financial Health
The company reported revenue of $66.98M for the trailing twelve months, yet simultaneously recorded a net income of $-71,537,000 and an EBITDA of $-68,132,000. The significant gap between the positive revenue of $66.98M and the substantial negative net income reveals a cost structure where operating expenses, such as research and development and general administrative costs, heavily outweigh the revenue generated by current sales activities. Furthermore, the company generated free cash flow of $-1,043,125, which indicates that the business is currently consuming cash reserves to fund its operations and development pipeline rather than generating surplus liquidity for distribution. When analyzing profitability metrics, the company demonstrates a gross margin of 100.0%, reflecting that the cost of goods sold is negligible relative to revenue in the biotechnology development stage. However, this is contrasted by an operating margin of -60.5% and a profit margin of -106.8%, indicating that overhead costs and R&D expenditures are consuming more than the total revenue, resulting in a loss on every dollar of sales. Regarding balance sheet strength, the company holds $185.85M in cash against $193.18M in debt, resulting in a debt-to-equity ratio of 152.60. This comparison shows that while the company is net indebted, the substantial cash position provides a buffer against its liabilities, though the leverage remains significant for a development-stage entity. Additionally, the current ratio stands at 4.44, which signals that the company possesses a robust level of short-term liquidity relative to its short-term obligations, ensuring it can meet immediate financial commitments without distress. Finally, the return on equity is -60.0% and the return on assets is -13.5%, metrics that reveal that management has not yet generated positive returns on shareholder capital or total assets, a common characteristic for companies in the clinical development phase before commercialization.
Valuation Assessment
Valuation metrics for Enanta Pharmaceuticals reflect its lack of profitability, as evidenced by a trailing P/E ratio of N/A and a forward P/E of -4.91. The absence of a trailing P/E implies that the company is currently unprofitable on a historical basis, while the negative forward P/E suggests that earnings are expected to remain negative in the coming year unless significant operational efficiencies or commercial milestones are achieved. The price-to-book ratio is 2.79, indicating that the market values the company at a premium of 179% above its book value, likely due to the perceived potential of its intellectual property and pipeline assets rather than current earnings power. Alternative valuation metrics provide further context, with a price-to-sales ratio of 5.27 and an EV/EBITDA of -5.29, suggesting that investors are pricing the stock based on revenue multiples and enterprise value relative to losses rather than earnings yield. Price volatility is assessed through the 52-week high of $17.15 and the 52-week low of $4.09, where the current trading price sits significantly below the high, reflecting the uncertainty surrounding the company's clinical outcomes and commercial launch timeline. The beta value is 0.97, which indicates that the stock's price volatility closely tracks the movement of the broader market, suggesting it does not exhibit extreme defensive or aggressive characteristics relative to the S&P 500.
Growth & Income
Revenue growth for the company is reported at 9.8% year-over-year, while earnings growth is N/A due to the absence of profitability. The divergence between positive revenue growth and negative earnings growth implies that top-line expansion is occurring, but it is insufficient to cover the high fixed costs associated with research, development, and administrative functions. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning that the firm retains all of its cash flow and earnings to reinvest into its growth initiatives, such as advancing EDP-514 through clinical phases. This strategy of reinvestment rather than distribution is typical for biotechnology firms that prioritize expanding their product pipeline over returning capital to shareholders while they are still developing their therapies. Overall, the growth and income profile is characterized by moderate top-line expansion coupled with significant financial losses and no current income distribution, positioning the company as a pure-play growth investment dependent on future commercial success.